Concerned about bladder cancer? Cxbladder can give you answers
Cxbladder is a suite of non-invasive genomic tests optimized to help rule out urothelial bladder cancer in patients being monitored for recurrent non-muscle invasive disease, and in those presenting with microhematuria, blood in urine that is invisible to the naked eye and confirmed via testing.
Cxbladder is an easy-to-use urine test that can reduce the need for invasive procedures when patients are at a low risk of disease.
Genomic testing optimized for the risk stratification of urothelial cancer
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease.
The Cxbladder suite of tests is supported by over 25 peer reviewed publications and Cxbladder Triage is now included in the AUA Microhematuria Guideline.
Optimize your clinical practice while improving the patient experience
The Cxbladder suite helps you prioritize your time and clinical resources on those that need it the most, streamlining practice workflow and increasing overall efficiency.
Cxbladder works for both you and the patient. Spare patients with a low probability of urothelial cancer the discomfort, anxiety and risks of an invasive procedure. With urine-based sampling and the option of in-home sample collection, the Cxbladder suite allows you to optimize your clinical practice while delivering the best patient experience possible.
Cxbladder for patients
The Cxbladder suite
Learn more about the Cxbladder suite of non-invasive genomic urine tests designed to rule out urothelial bladder cancer, the most common form of the disease.
The sampling system
Learn more about Cxbladder's easy-to-use and non-invasive sampling system, including the option of in-home sampling.
The science
Cxbladder is an advanced laboratory test that analyzes biomarker genes to help rule-out disease.
Latest news
Medicare Coverage Update for US Cxbladder Customers
Novitas has finalized an LCD for Genetic Testing in Oncology that removed coverage for Medicare beneficiaries for Cxbladder tests effective on April 24, 2025. In this update we discuss our response and what this means for US Cxbladder customers going forward.
Cxbladder Bulletin - April 2025
Pacific Edge invites you to read the April 2025 edition of the Cxbladder Bulletin clinician newsletter.
Cxbladder's Clinical Utility in Focus at AUA 2025
Recognition of Cxbladder’s clinical and economic value in evaluating patients presenting with hematuria is set to gain momentum at the American Urological Association’s (AUA) Annual Meeting, April 26–29 in Las Vegas.
Cxbladder Guideline Inclusion to Feature at SESAUA
The inclusion of Cxbladder Triage in a February 2025 amendment to the American Urology Association (AUA) Microhematuria Guideline is set to headline a symposium at the Annual Meeting of the Southeastern Section of the AUA (SESAUA) to be held 12-15 March in Nashville, Tennessee.